EC Number   |
Recommended Name |
Application |
|---|
    1.1.1.2 | alcohol dehydrogenase (NADP+) |
medicine |
- |
| 1.1.1.44 | phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating) |
medicine |
- |
| 1.1.3.41 | alditol oxidase |
medicine |
- |
| 1.3.1.14 | dihydroorotate dehydrogenase (NAD+) |
medicine |
- |
| 1.3.3.5 | bilirubin oxidase |
medicine |
- |
| 1.3.5.2 | dihydroorotate dehydrogenase (quinone) |
medicine |
- |
| 1.4.3.14 | L-lysine oxidase |
medicine |
- |
| 1.5.1.15 | methylenetetrahydrofolate dehydrogenase (NAD+) |
medicine |
- |
| 1.6.2.2 | cytochrome-b5 reductase |
medicine |
- |
| 1.8.1.12 | trypanothione-disulfide reductase |
medicine |
- |
| 1.13.11.5 | homogentisate 1,2-dioxygenase |
medicine |
- |
| 1.14.14.154 | sterol 14alpha-demethylase |
medicine |
- |
| 1.14.99.24 | steroid 9alpha-monooxygenase |
medicine |
- |
| 1.17.1.8 | 4-hydroxy-tetrahydrodipicolinate reductase |
medicine |
- |
| 2.1.1.45 | thymidylate synthase |
medicine |
- |
| 2.1.1.67 | thiopurine S-methyltransferase |
medicine |
- |
| 2.1.2.2 | phosphoribosylglycinamide formyltransferase 1 |
medicine |
- |
| 2.1.2.3 | phosphoribosylaminoimidazolecarboxamide formyltransferase |
medicine |
- |
| 2.3.1.7 | carnitine O-acetyltransferase |
medicine |
- |
| 2.3.1.56 | aromatic-hydroxylamine O-acetyltransferase |
medicine |
- |
| 2.3.1.61 | dihydrolipoyllysine-residue succinyltransferase |
medicine |
- |
| 2.3.3.10 | hydroxymethylglutaryl-CoA synthase |
medicine |
- |
| 2.4.1.80 | ceramide glucosyltransferase |
medicine |
- |
| 2.4.2.1 | purine-nucleoside phosphorylase |
medicine |
- |
| 2.5.1.2 | thiamine pyridinylase |
medicine |
- |
| 2.5.1.58 | protein farnesyltransferase |
medicine |
- |
| 2.6.1.44 | alanine-glyoxylate transaminase |
medicine |
- |
| 2.6.1.76 | diaminobutyrate-2-oxoglutarate transaminase |
medicine |
- |
| 2.7.7.38 | 3-deoxy-manno-octulosonate cytidylyltransferase |
medicine |
- |
| 2.7.11.26 | tau-protein kinase |
medicine |
- |
| 3.1.6.2 | steryl-sulfatase |
medicine |
- |
| 3.1.6.8 | cerebroside-sulfatase |
medicine |
- |
| 3.2.1.11 | dextranase |
medicine |
- |
| 3.2.1.45 | glucosylceramidase |
medicine |
- |
| 3.2.2.22 | rRNA N-glycosylase |
medicine |
- |
| 3.4.22.27 | cathepsin S |
medicine |
- |
| 3.4.22.40 | bleomycin hydrolase |
medicine |
- |
| 3.4.23.47 | HIV-2 retropepsin |
medicine |
- |
| 3.5.2.2 | dihydropyrimidinase |
medicine |
- |
| 3.5.2.9 | 5-oxoprolinase (ATP-hydrolysing) |
medicine |
- |
| 3.5.4.1 | cytosine deaminase |
medicine |
- |
| 3.5.4.5 | cytidine deaminase |
medicine |
- |
| 3.6.4.7 | peroxisome-assembly ATPase |
medicine |
- |
| 3.6.5.3 | protein-synthesizing GTPase |
medicine |
- |
| 3.7.1.3 | kynureninase |
medicine |
- |
| 7.2.2.3 | P-type Na+ transporter |
medicine |
- |
| 1.6.5.2 | NAD(P)H dehydrogenase (quinone) |
medicine |
(+-)-dunnione and its ortho-quinone analogues act as substrates. The biological activity is favored by the presence of methyl group at the C ring and methoxy group at the A ring. The ortho-quinones exert their antitumor activity through NQO1-mediated reactive oxygen species production by redox cycling |
| 4.4.1.20 | leukotriene-C4 synthase |
medicine |
(-1072)GNA and (-444)ANC promoter polymorphisms of LTC4 synthase influence risk of transient ischemic attack and ischemic stroke, but not risk of ischemic heart disease/coronary atherosclerosis, asthma, or chronic obstructive pulmonary disease in a Danish population. The (-1072)A allele has a frequency of 0.07 while the (-444)C allele has a frequency of 0.29. The (-1072)A and (-444)C alleles are on different haplotypes, thus one polymorphism cannot tag the other. Genetically altered leukotriene C4 synthase activity may play a role in thrombi formation rather than the development of atherosclerosis |
| 3.4.14.5 | dipeptidyl-peptidase IV |
medicine |
(2-(4-((2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl)-2-oxoethyl)amino)-4-methyl-1-piperidinyl)-4-pyridinecarboxylic acid (i. e. ABT-279) is a very potent, selective, effective, and well-tolerated inhibitor useful for the treatment of diabetes |
| 3.4.14.5 | dipeptidyl-peptidase IV |
medicine |
(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide is a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes |
| 1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
medicine |
(pro)renin receptor is constitutively expressed in renal glomeruli and tubules. Expression of the receptor is upregulated in diabetes via enhancement of angiotensin subtype 1 receptor-NADPH oxidase activity |
| 3.5.1.98 | histone deacetylase |
medicine |
1,2,4-oxadiazole-containing hydroxamic acid derivatives are discovered as histone deacetylase inhibitors for potential application in cancer therapy |
| 3.2.1.63 | 1,2-alpha-L-fucosidase |
medicine |
1,2-alpha-L-fucosynthase, derived from an inverting alpha-glycosidase (AfcA) and from a glycosidase with an unusual reaction mechanism, may serve as a promising tool to create biologically active compounds that can be used not only for prebiotics but also for clinical treatments aimed to regulate various cellular processes and infectious diseases |
| 3.4.24.86 | ADAM 17 endopeptidase |
medicine |
1,25-dihydroxyvitamin D inhibition of TACE is a potential common mechanism underlying the efficacy of therapy with 1,25-dihydroxyvitamin D or its analogs to improve outcomes in chronic kidney disease. 1,25-dihydroxyvitamin D prevents/moderates not only the onset and progression of parathyroid TACE/TGFalpha-driven secondary hyperparathyroidism, but renal TACE/TGFalpha-driven fibrotic and inflammatory lesions to the renal parenchyma, and TACE/TNFalpha-driven systemic inflammation |
| 2.5.1.21 | squalene synthase |
medicine |
1-allyl-2-[3-(benzylamino)propoxy]-9H-carbazole shows 50% inhibition of enzyme at 63 nM, significant reduction of both plasma cholesterol and plasma triglyceride levels following oral dosing |
| 3.4.21.7 | plasmin |
medicine |
11% of patients with systemic reactions to Hymenoptera stings display increased serum baseline plasmin level and 70% of these have a history of anaphylaxis. Indication of bone marrow examination for the diagnosis of clonal mast cell disease |
| 3.4.22.B30 | calpain 10 |
medicine |
111/121 diplotype of calpain-10 is associated with the risk of polycystic ovary syndrome in Korean women |
| 1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
medicine |
11beta-HSD1 inhibition may be a valid target for the treatment of diabetes |
| 1.1.1.B40 | 11beta-hydroxysteroid dehydrogenase (NAD+) |
medicine |
11beta-HSD1 is a drug target for treatment of insulin resistance, diabetes and cardiovascular disease |
| 1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
medicine |
11beta-HSD1 is a drug target for treatment of insulin resistance, diabetes and cardiovascular disease |
| 1.13.11.12 | linoleate 13S-lipoxygenase |
medicine |
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes |
| 1.13.11.31 | arachidonate 12-lipoxygenase |
medicine |
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
medicine |
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes |
| 1.1.1.141 | 15-hydroxyprostaglandin dehydrogenase (NAD+) |
medicine |
15-hydroxyprostaglandin dehydrogenase hypomorphic mice show a decreased level of enzyme mRNA and activity in all tissues examined. Mice show spontaneous preterm labor in the absence of progesterone withdrawal, and the onset of labor is preceded by prematurely increased concentrations of prostaglandin E2 and F2alpha. The fetal genotype plays a role in birth timing |
| 1.13.11.12 | linoleate 13S-lipoxygenase |
medicine |
15-LO-1 expression in colorectal carcinoma may contribute to the inhibition of metastatic capacity in vitro and can be exploited for therapeutic purposes |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
medicine |
15-LOX-1 and its metabolites (13-S-hydroxyoctadecadienoic acid and 15-S-hydroxyeicosatetraenoic acid) have anti-carcinogenic effects in colorectal cancer. 15-LOX-1 is possibly of prognostic value in stage IV colon cancer survival |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
medicine |
15-LOX-2 is a negative regulator of tumor growth via downregulating angiogenesis |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
medicine |
15-LOX-2 may be a potential target in radiation-targeted therapy of head-and-neck cancer |
| 3.4.21.7 | plasmin |
medicine |
16% of patients with a history of systemic reaction to Hymenoptera and Diptera venom show an elevated level of plasmin. These patients report fewer usual skin reactions, more flushing and frequently do not present skin reaction. Mastocytosis was diagnosed in 33% of patients with elevated plasmin level |
| 2.7.11.10 | IkappaB kinase |
medicine |
17-acetoxyjolkinolide B is a novel type NF-kappaB pathway inhibitor. Its unique interaction mechanism with IKK may render it a strong apoptosis inducer of tumor cells and a novel type anticancer drug candidate |
| 3.4.17.23 | angiotensin-converting enzyme 2 |
medicine |
17-beta-estradiol may reduce SARS-CoV-2 infection of lung epithelial cells |
| 3.4.21.B60 | transmembrane protease serine 2 |
medicine |
17-beta-estradiol may reduce SARS-CoV-2 infection of lung epithelial cells |
| 5.3.99.3 | prostaglandin-E synthase |
medicine |
17beta-estradiol and proinflammatory cytokines can act together to up-regulate PTGES, the finding supports a model whereby estrogens and inflammatory factors orchestrate a complex network of cross talk and feedback mechanisms that can contribute to hormone-dependent breast tumor growth and progression |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
medicine |
17beta-HSD1 inhibitors such as STX1040 may provide a treatment for hormone-dependent breast cancer |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
medicine |
17beta-HSD1 is an attractive target for the treatment of mammary tumours |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
medicine |
17beta-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
medicine |
17beta-hydroxysteroid dehydrogenase type 2 is mainly involved in the conversion of estradiol into estrone. Their ratio is decreased from 9/1 to 7/3 after over-expression of 17beta-hydroxysteroid dehydrogenase type 2 in MCF-7 cells already over-expressing 17beta-hydroxysteroid dehydrogenase type 1. The ratio is further decreased by the addition of the oxidative cofactor, NAD, to the cell culture to facilitate the estradiol to estrone conversion catalyzed by 17beta-hydroxysteroid dehydrogenase type 2 |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
medicine |
17betaHSD1 is an important prognostic factor in non-small cell lung carcinoma, NSCLC, patients and targeting 17betaHSD1 activity may further improve the clinical response in estrogen responsive NSCLC patients |
| 1.2.1.5 | aldehyde dehydrogenase [NAD(P)+] |
medicine |
19 ALDH genes are identified in the human genome and mutations in these genes and subsequent inborn errors in aldehyde metabolism are the molecular basis of several diseases, including Sjögren-Larsson syndrome, type II hyperprolinemia, gamma-hydroxybutyric aciduria and pyridoxine-dependent seizures. ALDH enzymes also play important roles in embryogenesis and development, neurotransmission, oxidative stress and cancer. ALDH enzymes display multiple catalytic and non-catalytic functions including ester hydrolysis, antioxidant properties, xenobiotic bioactivation and UV light absorption |
| 3.1.4.37 | 2',3'-cyclic-nucleotide 3'-phosphodiesterase |
medicine |
2',3'-cyclic nucleotide 3'-phosphodiesterase single nucleotide polymorphism rs2070106 is potentially associated with schizophrenia |
| 3.2.1.52 | beta-N-acetylhexosaminidase |
medicine |
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol, N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol, and N-butyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol are potent and selective inhibitors of beta-N-acetylhexosaminidase and may be useful as therapeutic agents for treating adult Tay-Sachs and Sandhoff diseases |
| 3.5.3.18 | dimethylargininase |
medicine |
2-chloroacetamidine may potentially find wide applicability as a general pharmacophore, useful in delineating characteristics of the amidinotransferase superfamily |
| 4.1.2.14 | 2-dehydro-3-deoxy-phosphogluconate aldolase |
medicine |
2-keto-3-deoxy-6-phosphogluconate aldolase is an attractive target for drug therapy in the case of human Streptococcus suis infections |
| 3.4.24.26 | pseudolysin |
medicine |
2-mercaptoacetyl-L-phenylalanyl-L-leucine represents a class of potent elastase inhibitors that might prove useful in the management of Pseudomonas aeruginosa infections |
| 3.1.6.2 | steryl-sulfatase |
medicine |
2-phenylindole sulfamates with antiproliferative activity in breast cancer cells are devoid of estrogenic activity and have the potential for in vivo application as steroid sulfatase inhibitors in the treatment of hormone-dependent breast cancer |
| 4.3.1.4 | formimidoyltetrahydrofolate cyclodeaminase |
medicine |
23 out of 38 patients with type 2 autoimmune hepatitis are positive for antibodies against enzyme, epitopes are mainly in formiminotransferase region |
| 2.7.1.1 | hexokinase |
medicine |
28-homobrassinolide is able to protect or restore the native structure of hexokinase when exposed to diabetic levels of glucose |
| 1.14.14.1 | unspecific monooxygenase |
medicine |
2fold increase in enzyme activity on diet of total parenteral nutrition plus choline |
| 2.3.3.8 | ATP citrate synthase |
medicine |
3,5-dichloro-2-hydroxy-N-(4-methoxybiphenyl-3-yl)benzenesulfonamide is a cell-permeable inhibitor with modest potency. It shows an oral availability of 55%, but a half-life of only 2.1 h. After 20 days of treatment, there is a modest lowering of both plasma cholesterol and triglycerides in high-fat fed mice |
| 2.3.1.286 | protein acetyllysine N-acetyltransferase |
medicine |
3-((2-methoxynaphthalen-1-yl)methyl)-7-((pyridin-3-ylmethyl)amino)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (ICL-SIRT078) has a significant neuroprotective effect in a lactacystin-induced model of Parkinsonian neuronal cell death in the N27 cell line and an optimised derivative thereof, is a candidate neuroprotective agent in in vivo models of Parkinson's disease |
| 4.1.3.4 | hydroxymethylglutaryl-CoA lyase |
medicine |
3-hydroxy-3-methylglutaric aciduria is an autosomal recessive branched chain organic aciduria caused by the deficiency of the enzyme 3-hydroxy-3-methylglutaryl-CoA lyase |
| 4.1.3.4 | hydroxymethylglutaryl-CoA lyase |
medicine |
3-hydroxy-3-methylglutaryl CoA lyase deficiency is a rare autosomal recessive mitochondrial disease characterized by a deficiency in the enzyme 3-hydroxy-3-methylglutaryl CoA lyase |
| 4.1.3.4 | hydroxymethylglutaryl-CoA lyase |
medicine |
3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency is a rare inborn error affecting leucine catabolism and ketogenesis, usually presenting in the neonatal period |
| 4.1.3.4 | hydroxymethylglutaryl-CoA lyase |
medicine |
3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency may cause hypoglycaemia which can lead to death |
| 2.3.1.16 | acetyl-CoA C-acyltransferase |
medicine |
3-ketoacyl coenzyme-A thiolase inhibition could be a treatment for patients with heart failure |
| 4.3.3.1 | 3-ketovalidoxylamine C-N-lyase |
medicine |
3-ketovalidoxylamine C-N-lyase is one of three key enzymes in the production of valienamine, which is a potent glucosidase inhibitor from validamycin A. Increasing incidence of diabetes has focused attention on glucosidase inhibitors. |
| 1.6.5.2 | NAD(P)H dehydrogenase (quinone) |
medicine |
3-nitrobenzanthrone is capable to induce NQO1 and CYP1A1 in lungs and kidney of rats thereby enhancing its own genotoxic and carcinogenic potential |
| 1.2.3.1 | aldehyde oxidase |
medicine |
3-substituted quinoline triazolopyridine compounds used as c-Met kinase inhibitors are subject to aldehyde oxidase-mediated metabolism. Several compouinds are unstable in monkey liver cytosolic incubations. Small electron-donating groups at the 3-quinoline moiety make the analogs more susceptible to metabolism, whereas large 3-substituents may reverse the trend |
| 4.1.1.29 | sulfinoalanine decarboxylase |
medicine |
3.6% of patients suffering from autoimmune polyendocrine syndrome type 1 are positive for antibodies against the enzyme. Antibodies cross-react with glutamic acid decarboxylase, aromatic L-amino acid decarboxylase and histidine decarboxylase |
| 1.3.1.22 | 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) |
medicine |
30 min incubation with dutasteride results in the lowest apparent Ki values overall and the lowest variation, significant for designing protocols for treatment and/or chemoprevention of prostatic diseases |
